In the latest edition of the Milken Institute Review, we examine if there could be a thriving market for good science in biopharmaceuticals that has lesser commercial prospects or is simply an ill-fit with corporate strategies. Here, we lay out the basic ingredients required to foster such a market, and describe alternative channels that could unlock the capital needed to leverage the full scope of innovation.
Creating Markets for Medical Innovation with Lower Commercial Potential: It's hard, but worth it.
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.